
July, 2025
Real-World Data Study Led by Dr. Salvia Jain Highlights Promising Treatment for Aggressive Blood Cancer
A new study led by PETAL investigator Dr. Salvia Jain demonstrates that a combination of two blood cancer medications is well tolerated, safe, and effective for patients with aggressive blood cancers who do not respond to standard therapy. The research, based on real-world data, is now featured in the Mass General Brigham Newsroom.
June, 2025
May, 2025
PETAL Consortium Featured in ASCO Post!
We are excited to share that PETAL Consortium is featured in the ASCO Post! The article highlights our groundbreaking study, which reveals how a specific sequence of therapies can significantly improve survival rates for patients with relapsed/refractory T- and NK-cell lymphomas. By leveraging global data from PETAL, we are moving closer to refining treatment strategies and providing new hope for patients with limited treatment options.
Forecasting Optimal Treatments in Relapsed/Refractory Mature T- and NK-Cell Lymphomas – The PETAL Consortium’s latest paper published in the British Journal of Haematology.

April, 2025
March, 2025
PETAL Consortium at the TCLF 2025 shared their ongoing projects and work through multiple compelling oral and poster presentations.
February, 2025
MGH the founding site will be participating in the phase III trial of Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma.
An inspiring story shared by our PETAL patient on how Specialized Expertise Transformed a Critical Setback From Peripheral T-cell Lymphoma Into Hope
January, 2025
Blood Cancers Today spoke with researchers from the Salvia Jain Lab to learn more about the goals and initiatives of the PETAL Consortium. Leora Boussi, MD, Angela Koh, and Jessy Xinyi Han discuss their study of a novel scoring system using one of the largest international global cohorts of 925 patients with relapsed or refractory mature T-cell and NK-cell lymphomas.
PETAL has been prominently featured in the MGH Cancer Center Curtain Raiser and the Mass General Brigham Cancer Center newsletter, which reaches over 20,000 individuals across academia, industry, and other fields. We are excited to share key updates on our research with this wide audience.
We are pleased to share that the University of Pennsylvania (UPenn) is our third participating site which is now active for enrollment